RecruitingNot Applicable

High-Load, Low-Load, and Passive Blood Flow Restriction in Competitive Sprinters

Pakistan18 participantsStarted 2025-12-01

Plain-language summary

This randomized clinical trial will include competitive male and female sprinters aged 16-30 years, recruited through purposive sampling. Participants will be randomly assigned to one of three groups: (A) HL-BFR (70-85% 1RM with BFR during sets), (B) LL-BFR (20-30% 1RM with BFR), or (C) Passive BFR (BFR applied between sets). The intervention will consist of a 6-week sprint-specific resistance training program performed thrice weekly, incorporating resisted sprints, barbell step-ups, hip thrusts, Nordic curls, and bounding exercises. Strength will be measured using 1RM testing, explosive power through countermovement and standing broad jumps, and sprint performance via 10m, 30m, and 100m timed sprints. Subjective exertion will be tracked using the sRPE scale. The study aims to determine whether HL-BFR, LL-BFR, or passive BFR produces superior improvements in sprint performance and neuromuscular strength. It is hypothesized that HL-BFR may yield greater adaptations due to combined mechanical and metabolic stress, though LL-BFR and passive BFR may offer practical, low-impact alternatives.

Who can participate

Age range

18 Years – 30 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age between 16-30 years * Competitive sprinters with at least 2 years of sprint-specific training * Healthy individuals without cardiovascular, metabolic, musculoskeletal, or neurological disorders * Willingness to participate in a 6-week training program Exclusion Criteria: * Pregnancy or lactation * Cardiovascular, vascular, pulmonary, renal or metabolic disorders * Uncontrolled hypertension * Recent significant weight loss * Use of performance-enhancing drugs within past 2 months * Any medical condition preventing safe participation

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Lower Limb Muscle Strength (1RM Test)

Timeframe: Baseline (Week 0) and Post-Intervention (Week 6)

Trial details

NCT IDNCT07438535

SponsorRiphah International University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-08-01

Contact for this trial

Danish Hassan, PhD

+92 345 7946009 danish.hassan009@gmail.com

View on ClinicalTrials.gov More Blood Flow Restriction trials